title: Steroid combination therapy and detoxification enzyme gene polymorphisms in sudden sensorineural hearing loss patients.
abstract: OBJECTIVE
  The purpose of this study was to evaluate the relations among the combined therapy with steroid and the detoxification enzyme gene polymorphisms in patients with sudden sensorineural hearing loss (SSNHL). The pathogenetic mechanism of inner ear dysfunction could involve an increase in lipid peroxidation and a decrease in cellular antioxidant defense. Glutathione S-transferases (GSTs) and cytochrome P450 (CYP) belong to a system of detoxification and antioxidant enzymes that have been demonstrated in the inner ear.
  
  
  METHODS
  A prospective study in patients with SSNHL.
  
  
  METHODS
  All 441 subjects were genotyped for GSTM1, GSTT1, and CYP1A1 polymorphisms. The polymorphisms were analyzed by polymerase chain reaction amplification, restriction enzyme digestion, and deoxyribonucleic acid fragment separation by electrophoresis.
  
  
  RESULTS
  No significant difference was observed between SSNHL patients and controls in 3 polymorphisms. However, the prevalence of the partial recovery group in patients with the CC genotype of CYP1A1 (22%) was higher than that in the complete recovery (7.4%) or no recovery group (12.5%) for the subjects classified according to modified Siegel's criteria but were not statistically significant.
  
  
  CONCLUSIONS
  This is the first approach to analyze gene polymorphism and efficacy of clinical treatment of patients with SSNHL, although the observations do not confirm the effect of the GSTM1/T1 and CYP1A1 genotypes as a risk factor for SSNHL.
authors.affiliation: Department of Pharmacology, College of Oriental Medicine, Institute of Oriental Medicine, Kyung Hee University, Seoul, Republic of Korea. jyum@khu.ac.kr
authors.forename: Jae-Young
authors.initials: JY
authors.lastname: Um
authors.forename: Chul-Ho
authors.initials: CH
authors.lastname: Jang
authors.forename: Su-Jin
authors.initials: SJ
authors.lastname: Kim
authors.forename: Hye-Lin
authors.initials: HL
authors.lastname: Kim
authors.forename: Seon-Young
authors.initials: SY
authors.lastname: Kim
authors.forename: Young-Bum
authors.initials: YB
authors.lastname: Cho
authors.forename: Seung-Heon
authors.initials: SH
authors.lastname: Hong
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D019363:Cytochrome P-450 CYP1A1 / Q000235:genetics*; D005260:Female; D005838:Genotype; D005982:Glutathione Transferase / Q000235:genetics*; D006319:Hearing Loss, Sensorineural / Q000188:drug therapy / Q000235:genetics*; D003639:Hearing Loss, Sudden / Q000188:drug therapy / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D011446:Prospective Studies; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D019363:Cytochrome P-450 CYP1A1; D005982:Glutathione Transferase; C413545:glutathione S-transferase T1